
Dr. Gaurav Kharya is an experienced Paediatric Haematologist and Bone Marrow Transplant specialist, with professional associations in paediatric haematology and oncology at hospitals in Delhi NCR. His clinical focus includes the diagnosis and management of childhood blood disorders, paediatric cancers and conditions requiring specialised bone marrow transplantation.
He completed his MBBS from Netaji Subhash Chandra Bose Medical College, Jabalpur, followed by a Diploma in Child Health (DCH) from Baba Raghav Das Medical College, Gorakhpur. He subsequently obtained DNB in Paediatrics from Sir Ganga Ram Hospital, New Delhi, and completed specialised fellowships in Paediatric Haematology-Oncology and Bone Marrow Transplantation in India and the United Kingdom.
His areas of clinical expertise include paediatric leukaemia, blood disorders, bone marrow failure syndromes and haematological malignancies. He also specialises in bone marrow transplantation using matched sibling donors, partially matched family donors, unrelated donors, haploidentical donors and cord blood transplantation.
Dr. Kharya has previously worked at Sir Ganga Ram Hospital, New Delhi, St. Mary's Hospital in London and the Great North Children's Hospital in Newcastle, United Kingdom. His professional background includes clinical training in paediatric haematology, oncology and stem cell transplantation, along with research publications in paediatric blood disorders.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Gaurav Kharya for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Gaurav Kharya regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Gaurav Kharya holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.